WO1999026625A1 - Formulations comprising dissolved paroxetine - Google Patents
Formulations comprising dissolved paroxetine Download PDFInfo
- Publication number
- WO1999026625A1 WO1999026625A1 PCT/GB1998/003471 GB9803471W WO9926625A1 WO 1999026625 A1 WO1999026625 A1 WO 1999026625A1 GB 9803471 W GB9803471 W GB 9803471W WO 9926625 A1 WO9926625 A1 WO 9926625A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- paroxetine
- solid
- carrier
- capsule
- capsules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU11680/99A AU1168099A (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
EA200000552A EA200000552A1 (en) | 1997-11-21 | 1998-11-18 | READY PREPARATIVE FORMS CONTAINING DISSOLVED PAROXETIN |
PL98340555A PL340555A1 (en) | 1997-11-21 | 1998-11-18 | Preparations containing dissolved paroxetin |
HU0100580A HUP0100580A3 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
SK734-2000A SK7342000A3 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
CA002310407A CA2310407A1 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
EP98954631A EP1033986A1 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
KR1020007005532A KR20010032320A (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
JP2000521827A JP2001523718A (en) | 1997-11-21 | 1998-11-18 | Formulations containing dissolved paroxetine |
BR9814220-8A BR9814220A (en) | 1997-11-21 | 1998-11-18 | Formulations comprising paroxetine dissolved |
APAP/P/2000/001821A AP2000001821A0 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine. |
IL13610698A IL136106A0 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
NO20002590A NO20002590L (en) | 1997-11-21 | 2000-05-19 | Formulations comprising dissolved paroxetine |
BG104527A BG104527A (en) | 1997-11-21 | 2000-06-13 | Formulations comprising dissolved paroxetine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9724544.3A GB9724544D0 (en) | 1997-11-21 | 1997-11-21 | Novel Formulation |
GB9724544.3 | 1997-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999026625A1 true WO1999026625A1 (en) | 1999-06-03 |
Family
ID=10822374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/003471 WO1999026625A1 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1033986A1 (en) |
JP (1) | JP2001523718A (en) |
KR (1) | KR20010032320A (en) |
CN (1) | CN1279608A (en) |
AP (1) | AP2000001821A0 (en) |
AR (1) | AR015485A1 (en) |
AU (1) | AU1168099A (en) |
BG (1) | BG104527A (en) |
BR (1) | BR9814220A (en) |
CO (1) | CO4970832A1 (en) |
DZ (1) | DZ2658A1 (en) |
EA (1) | EA200000552A1 (en) |
GB (1) | GB9724544D0 (en) |
HU (1) | HUP0100580A3 (en) |
IL (1) | IL136106A0 (en) |
MA (1) | MA24704A1 (en) |
NO (1) | NO20002590L (en) |
OA (1) | OA11385A (en) |
PE (1) | PE20000381A1 (en) |
PL (1) | PL340555A1 (en) |
SK (1) | SK7342000A3 (en) |
TR (1) | TR200001423T2 (en) |
WO (1) | WO1999026625A1 (en) |
ZA (1) | ZA9810637B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058116A2 (en) * | 1998-05-13 | 1999-11-18 | Smithkline Beecham Plc | Novel formulation containing paroxetine |
WO2000054775A1 (en) * | 1999-03-12 | 2000-09-21 | Basf Ag | Stable pharmaceutical application form for paroxetin anhydrate |
WO2001001956A2 (en) * | 1999-07-02 | 2001-01-11 | Knoll Aktiengesellschaft | Solid preparations containing paroxetine |
US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
US6984632B1 (en) | 1999-07-01 | 2006-01-10 | Italfarmaco S.P.A. | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
AU2002364212B2 (en) * | 2001-12-21 | 2007-09-20 | Shire Laboratories Inc. | Oral capsule formulation with increased physical stability |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0200475D0 (en) * | 2002-02-15 | 2002-02-15 | Ltp Lipid Technologies Provide | Oral pharmaceutical preparation |
EP2510924B1 (en) * | 2009-12-08 | 2014-10-08 | IL Hwa Co., Ltd | SOLID DISPERSIONS CONTAINING 20-O-ß-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL |
GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
CN103961333B (en) * | 2014-05-07 | 2020-02-21 | 浙江华海药业股份有限公司 | Paroxetine mesylate capsule and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031197A1 (en) * | 1995-04-03 | 1996-10-10 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
WO1998031365A1 (en) * | 1997-01-15 | 1998-07-23 | Smithkline Beecham Plc | Paroxetine compositions |
-
1997
- 1997-11-21 GB GBGB9724544.3A patent/GB9724544D0/en not_active Ceased
-
1998
- 1998-11-18 HU HU0100580A patent/HUP0100580A3/en unknown
- 1998-11-18 PL PL98340555A patent/PL340555A1/en unknown
- 1998-11-18 PE PE1998001126A patent/PE20000381A1/en not_active Application Discontinuation
- 1998-11-18 WO PCT/GB1998/003471 patent/WO1999026625A1/en not_active Application Discontinuation
- 1998-11-18 DZ DZ980268A patent/DZ2658A1/en active
- 1998-11-18 SK SK734-2000A patent/SK7342000A3/en unknown
- 1998-11-18 AU AU11680/99A patent/AU1168099A/en not_active Abandoned
- 1998-11-18 CN CN98811404A patent/CN1279608A/en active Pending
- 1998-11-18 EP EP98954631A patent/EP1033986A1/en not_active Withdrawn
- 1998-11-18 AP APAP/P/2000/001821A patent/AP2000001821A0/en unknown
- 1998-11-18 JP JP2000521827A patent/JP2001523718A/en active Pending
- 1998-11-18 EA EA200000552A patent/EA200000552A1/en unknown
- 1998-11-18 KR KR1020007005532A patent/KR20010032320A/en not_active Application Discontinuation
- 1998-11-18 BR BR9814220-8A patent/BR9814220A/en not_active Application Discontinuation
- 1998-11-18 TR TR2000/01423T patent/TR200001423T2/en unknown
- 1998-11-18 IL IL13610698A patent/IL136106A0/en unknown
- 1998-11-19 AR ARP980105880A patent/AR015485A1/en unknown
- 1998-11-19 MA MA25357A patent/MA24704A1/en unknown
- 1998-11-20 ZA ZA9810637A patent/ZA9810637B/en unknown
- 1998-11-20 CO CO98068459A patent/CO4970832A1/en unknown
-
2000
- 2000-05-19 OA OA1200000153A patent/OA11385A/en unknown
- 2000-05-19 NO NO20002590A patent/NO20002590L/en not_active Application Discontinuation
- 2000-06-13 BG BG104527A patent/BG104527A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031197A1 (en) * | 1995-04-03 | 1996-10-10 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
WO1998031365A1 (en) * | 1997-01-15 | 1998-07-23 | Smithkline Beecham Plc | Paroxetine compositions |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058116A3 (en) * | 1998-05-13 | 2000-02-17 | Smithkline Beecham Plc | Novel formulation containing paroxetine |
WO1999058116A2 (en) * | 1998-05-13 | 1999-11-18 | Smithkline Beecham Plc | Novel formulation containing paroxetine |
JP4854115B2 (en) * | 1999-03-12 | 2012-01-18 | エイシカ ファーマシューティカルス リミテッド | Stable formulation for anhydrous paroxetine |
WO2000054775A1 (en) * | 1999-03-12 | 2000-09-21 | Basf Ag | Stable pharmaceutical application form for paroxetin anhydrate |
US6596309B2 (en) | 1999-03-12 | 2003-07-22 | Basf Aktiengesellschaft | Stable pharmaceutical dosage form for paroxetin anhydrate |
JP2004527447A (en) * | 1999-03-12 | 2004-09-09 | バスフ アクチェンゲゼルシャフト | Stable formulation for anhydrous paroxetine |
US6984632B1 (en) | 1999-07-01 | 2006-01-10 | Italfarmaco S.P.A. | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
WO2001001956A2 (en) * | 1999-07-02 | 2001-01-11 | Knoll Aktiengesellschaft | Solid preparations containing paroxetine |
WO2001001956A3 (en) * | 1999-07-02 | 2001-07-12 | Knoll Ag | Solid preparations containing paroxetine |
US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
AU2002364212B2 (en) * | 2001-12-21 | 2007-09-20 | Shire Laboratories Inc. | Oral capsule formulation with increased physical stability |
WO2006119779A3 (en) * | 2005-05-10 | 2007-06-14 | Lifecycle Pharma As | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
Also Published As
Publication number | Publication date |
---|---|
EA200000552A1 (en) | 2000-10-30 |
BG104527A (en) | 2001-04-30 |
IL136106A0 (en) | 2001-05-20 |
PE20000381A1 (en) | 2000-05-07 |
SK7342000A3 (en) | 2000-12-11 |
GB9724544D0 (en) | 1998-01-21 |
NO20002590L (en) | 2000-07-19 |
CN1279608A (en) | 2001-01-10 |
NO20002590D0 (en) | 2000-05-19 |
PL340555A1 (en) | 2001-02-12 |
KR20010032320A (en) | 2001-04-16 |
BR9814220A (en) | 2001-12-26 |
ZA9810637B (en) | 2000-05-22 |
TR200001423T2 (en) | 2000-10-23 |
AU1168099A (en) | 1999-06-15 |
JP2001523718A (en) | 2001-11-27 |
HUP0100580A3 (en) | 2002-05-28 |
AP2000001821A0 (en) | 2000-06-30 |
CO4970832A1 (en) | 2000-11-07 |
EP1033986A1 (en) | 2000-09-13 |
DZ2658A1 (en) | 2003-03-22 |
MA24704A1 (en) | 1999-07-01 |
OA11385A (en) | 2004-01-27 |
AR015485A1 (en) | 2001-05-02 |
HUP0100580A2 (en) | 2002-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6596308B2 (en) | Controlled release pharmaceutical composition | |
AU2006311818B9 (en) | Improved delivery of tetrahydrocannabinol | |
US8293270B2 (en) | Lipophilic vehicle-based dual controlled release matrix system | |
TWI490216B (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
RU2278657C2 (en) | Microemulsion preconcentrate | |
US20160184258A1 (en) | Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts | |
US20140357708A1 (en) | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery | |
DK170209B1 (en) | Ranitidine-containing capsule preparation and non-aqueous liquid preparation | |
WO2002011701A1 (en) | A controlled release pharmaceutical composition | |
JP2001523705A (en) | Drug delivery system using liquid crystal structure | |
AU2016203127B2 (en) | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts | |
EP1033986A1 (en) | Formulations comprising dissolved paroxetine | |
US20060029661A1 (en) | Orally administrable pharmaceutical formulation | |
US11026893B2 (en) | Taste masking drug formulations | |
AU2013213706B2 (en) | An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery | |
US20020032220A1 (en) | Formulations comprising dissolved paroxetine | |
EP1485081B1 (en) | Ibuprofen solution for hard shell capsules | |
CA2310407A1 (en) | Formulations comprising dissolved paroxetine | |
WO2021163023A1 (en) | Stable formulations of dronabinol | |
MXPA00005030A (en) | Formulations comprising dissolved paroxetine | |
JP2003504392A (en) | New pharmaceutical formulations | |
CZ20001876A3 (en) | Preparations containing dissolved paroxetine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 136106 Country of ref document: IL Ref document number: 98811404.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11680/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504485 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200000447 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7342000 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2310407 Country of ref document: CA Ref document number: 2310407 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/01423 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-1876 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007005532 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/005030 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998954631 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000552 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09554861 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998954631 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1876 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007005532 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998954631 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007005532 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-1876 Country of ref document: CZ |